<DOC>
	<DOC>NCT01257971</DOC>
	<brief_summary>This is a multi-centre non-interventional study of patients who are treated with any HMGCoA reductase inhibitor available in Croatia (rosuvastatin, simvastatin, atorvastatin and fluvastatin) for at least 6 months. All HMG-CoA reductase inhibitors must be prescribed in accordance with SmPCs approved in Croatia. Data collection for each patient will take place at a single visit. The investigator will complete a Case Report Form with the patient's demographics, the presence of the factors for high cardiovascular risk, current treatment, cholesterol values as well as with further treatment decision.</brief_summary>
	<brief_title>Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>patients who have been treated with one HMGCoA reductase inhibitor for at least 6 months without changing the dose for the last 4 weeks at least. All patients must sign Informed consent form. Patients who have not signed the Informed consent form. Patients with contraindication for the treatment with HMGCoA reductase inhibitors as per SmPC approved in Croatia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>HMG-CoA reductase inhibitor</keyword>
	<keyword>cardiovascular risk</keyword>
	<keyword>LDLl</keyword>
</DOC>